Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This taken from King’s college financial statement, we are definitely in good company!
Commercialisation
Although a less active year than last, when measured by equity volume, King's ranked fifth in UK and first in London, at f245m, with continued formation of new ventures and licence transactions.
• The King's spinout Quell Therapeutics entered into an agreement with AstraZeneca to develop, manufacture, and commercialise engineered T-regulatory cell therapies for autoimmune diseases (such as Type 1 diabetes (T1D) and inflammatory bowel disease (IBD). Quell will receive an $85 million upfront cash and equity investment from AstraZeneca. Quell is also eligible to receive over $2 billion for further development and commercialisation milestones and royalties, if successful. The collaboration combines Treg cell engineering and manufacturing expertise of Quell with AstraZeneca's developmental, commercial, and therapeutic capabilities.
• Cytolytix Limited was a new company formed in partnership with ValiRx plc to progress the preclinical development of its triple negative breast cancer treatment, CLX001 based on IP licensed from King's College London based on the work of Martin Ulmschneider and Charles Chen from the department of Chemistry (NMES)
• Hypervision Surgical Ltd, a spin-out company emerging from the work of Seb Ourselin, Tom Vercautern and Michael Ebner in the School of Biomedical Engineering & Imaging Sciences combined medical imaging technology and artificial intelligence (AI) to secure a seed investment of £6.5 million to develop real-time tissue analysis in the operating theatre that aims to make surgeries more precise, safer and faster.
• Theragnostics Ltd, a spin out formed by Greg Mullen (Imaging Sciences) and to which King's licensed the Galli® imaging biomarker technology at the centre of Theragnostics' proprietary platform was acquired by German private company Ariceum Therapeutics.
Wow, like the first deal!
Problem is you can have a bucket load of Jam tomorrow but none of it will pay today’s bills.
New inbound CEO once found will need more than just a few weeks cash runway ahead of them to turn this around, I stand by my call £1.5m raise at 1p IF they can secure support. It will be touch and go.
Porky has been super quiet recently, but since an excellent update RNS this week he has burst in to life 😂😂😂
Feeling a tad threatened that this is going to spring in to action soon?
Cash until H2 2025 without lab revenue so with lab revenue we should have decent cash in the bank until middle of 2025.
Interestingly, the more he wants a placing the more likely Valirx will end up getting a deal for CLX. CLX is no longer jam now they got the formulation right which is a big part of preclinical testing and early safety tests were fantastic.
Before the end of year 401 should be signed, 201 hopefully signed and CLX we will see. One would assume if they don't get 201 over the line then they will try for CLX so those not invested at these prices will likely miss out. Also 11 lab contracts at an advanced stage so plenty of opportunities for the SP to multibag first.
I think that CLX is a very interesting approach.
However, PM, where is the last RNS does it say that the early safety tests were fantastic?
This is what it does say:
"Testing is ongoing to assess the safety of the formulated product."
Nor is the 'formulation right' or is there 'Cash until H2 2025 without lab revenue'.
With 7 recommendations so far to PM's comment it suggests to me that a new cohort of investors have arrived, drawn in by the spike a few days ago. The BOD will be delighted to have them onboard as they will be adding to the pool of investors who might be happy to average down if they need to shift 2nd hand shares again.
There may even be enough new interest to facilitate a convertible loan deal.
During early stage preclinical testing:
CLX001 is a peptide that is intended to be delivered in a nanoformulation. While the nanoformulation is undergoing further optimisation, the unformulated peptide continues to undergo biological testing. Safety screen data generated in Q1 2023 confirms no immediate toxicology concerns. Regulatory planning activities have also been commenced.
Also peptides in general are very safe when used as drugs because they have very few side effects. Further information is on the website.
The biggest concern for CLX was getting the formulation right which is often difficult and based on a previous RNS it was a concern. I am personally not concerned about the safety aspect but obviously further testing is needed but if that passes the value would increase significantly. Don't forget the likes of SAR got to 200/300 million at one stage based on a preclinical drug so I think the upside is decent but it will depend if they need an early deal or to carry on.
https://www.valirx.com/cytolytix-limited